+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Anti-infective Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017-2025

  • ID: 4851769
  • Report
  • March 2018
  • Region: Global
  • 235 pages
  • Transparency Market Research
1 of 2
Anti-infective Drugs Market: Overview

This report studies the current as well as future prospects of the global anti-infective drugs market. Stakeholders of this report include companies and intermediaries engaged in the manufacture, commercialization, and provision of anti-infective drugs for pneumothorax and pleural effusion treatment as well as new players planning to enter this market. This report comprises an elaborate executive summary along with a market snapshot providing overall information of various segments and sub-segments considered in the scope of the study. This section also provides overall information and data analysis of the global anti-infective drugs market with respect to the leading market segments based on type, indication, distribution channel, and region.

Based on type, the global anti-infective drugs market has been segmented into anti-bacterial drugs, anti-fungal drugs, and anti-viral drugs. In terms of indication, the market has been classified into pneumonia, methicillin-resistant Staphylococcus aureus (MRSA), sepsis, tuberculosis, dermatophytosis, aspergillosis, candidiasis, hepatitis virus infection, HIV infection, respiratory virus infection, and others. Based on distribution channel, the global anti-infective drugs market has been divided into hospital pharmacy, retail pharmacy, and online sales.

Each of the market segments has been extensively analyzed based on market related factors such as incidence and prevalence of pneumonia, methicillin-resistant Staphylococcus aureus (MRSA), sepsis, tuberculosis, dermatophytosis, aspergillosis, candidiasis, hepatitis virus infection, HIV infection, and respiratory virus infection. Moreover, historical year-on-year growth has been taken into consideration while estimating the market size. The market size and forecast in terms of US$ Mn for each segment have been provided for the period from 2015 to 2025. The report also provides the compound annual growth rate (CAGR %) for each segment for the forecast period from 2017 to 2025, considering 2016 as the base year.

The market overview section of the report explores the market dynamics such as drivers, restraints, and opportunities that currently have a strong impact on the anti-infective drugs market and could influence the market in the near future. Market attractiveness analysis has been provided in the market overview section in order to explain the intensity of competition in the market across different regions. The competitive scenario among different market players is evaluated through market share analysis in the competitive landscape section of the report. All these factors would help market players to take strategic decisions in order to strengthen their positions and expand their shares in the global anti-infective drugs market.

Geographically, the global anti-infective drugs market has been segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The market size and forecast for each of these regions has been provided for the period from 2015 to 2025, along with their respective CAGRs for the forecast period from 2017 to 2025, considering 2016 as the base year. The report also provides market size and forecast for major countries in the respective regions. A detailed qualitative analysis of factors responsible for driving and restraining the market and future opportunities has been provided in the market overview section. This section of the report also provides market attractiveness analysis, Porter’s Five Forces analysis, and market share analysis by key players, thereby presenting a thorough analysis of the overall competitive scenario in the global anti-infective drugs market.

Key players operating in the global anti-infective drugs market are Merck & Co., Inc., Bayer AG, Pfizer, Inc., Gilead Sciences, GlaxoSmithKline plc, Novartis AG, Bristol-Myers Squibb, Sanofi, Allergen plc, F. Hoffman-La Roche Ltd., and Johnson and Johnson, among others.

The global anti-infective drugs market has been segmented as follows:

Global Anti-infective Drugs Market, by Type

Anti-bacterial Drugs

B-lactams
Quinolones
Macrolides
Tetracycline
Aminoglycoside
Others (sulfonamide, phenicols)

Anti-fungal Drugs

Azoles
Echinocandins
Polyenes
Others

Anti-viral Drugs

Global Anti-infective Drugs Market, by Indication

Pneumonia
Methicillin-resistant Staphylococcus Aureus (MRSA)
Sepsis
Tuberculosis
Dermatophytosis
Aspergillosis
Candidiasis
Hepatitis Virus Infection
HIV Infection
Respiratory Virus Infection
Others

Global Anti-infective Drugs Market, by Distribution Channel

Hospital Pharmacy
Retail Pharmacy
Online Sales

Global Anti-infective Drugs Market, by Region

North America

U.S.
Canada

Europe

Germany
France
Italy
Spain
U.K.
Rest of Europe

Asia Pacific

India
Japan
China
Australia & New Zealand
Rest of Asia Pacific

Latin America

Brazil
Mexico
Rest of Latin America

Middle East & Africa

GCC Countries
South Africa
Rest of Middle East & Africa
Note: Product cover images may vary from those shown
2 of 2
1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights

2. Assumptions and Research Methodology
2.1. Assumptions
2.2. Acronyms Used
2.3. Research Methodology

3. Executive Summary
3.1. Global Anti-infective Drugs Market Snapshot
3.2. Market Opportunity Map

4. Market Overview
4.1. Product Overview
4.2. Global Anti-infective Drugs Market Size (US$ Mn) Forecast, 2017-2025
4.3. Global Anti-infective Drugs Market Outlook
4.4. Key Industry Developments

5. Market Dynamics
5.1. Drivers and Restraints Snapshot Analysis
5.2. Drivers
5.3. Restraints
5.4. Opportunities
5.5. Key Trends
5.6. Porter’s Analysis
5.7. Pipeline Analysis
5.8. Disease Prevalence
5.9. Key Brand Analysis

6. Global Anti-infective Drugs Market Analysis, by Type
6.1. Key Findings
6.2. Introduction
6.3. Anti-infective Drugs Market Value Share Analysis, by Type
6.4. Anti-infective Drugs Market Forecast, by Type
6.4.1. Global Anti-infective Drugs Market Forecast, by Type - Anti-bacterial Drugs
6.4.1.1. B - Lactams
6.4.1.2. Quinolones
6.4.1.3. Macrolides
6.4.1.4. Tetracycline
6.4.1.5. Aminoglycoside
6.4.1.6. Others (Sulfonamide, Phenicols)
6.4.2. Global Anti-infective Drugs Market Forecast, by Type - Anti-fungal Drugs
6.4.2.1. Azoles
6.4.2.2. Echinocandins
6.4.2.3. Polyenes
6.4.2.4. Others
6.4.3. Global Anti-infective Drugs Market Forecast, by Type - Anti-viral Drugs
6.5. Anti-infective Drugs Market Analysis, by Type
6.6. Anti-infective Drugs Market Attractiveness Analysis, by Type
6.7. Market Trends

7. Anti-infective Drugs Market Analysis, by Disease Indication
7.1. Key Findings
7.2. Introduction
7.3. Anti-infective Drugs Market Value Share Analysis, by Disease Indication
7.4. Anti-infective Drugs Market Forecast, by Disease Indication
7.4.1. Pneumonia
7.4.2. Methicillin-resistant Staphylococcus Aureus (MRSA)
7.4.3. Sepsis
7.4.4. Tuberculosis
7.4.5. Dermatophytosis
7.4.6. Aspergillosis
7.4.7. Candidiasis
7.4.8. Hepatitis Virus Infection
7.4.9. HIV Infection
7.4.10. Respiratory Virus Infection
7.4.11. Others
7.5. Anti-infective Drugs Market Analysis, by Disease Indication
7.6. Anti-infective Drugs Market Attractiveness Analysis, by Disease Indication
7.7. Key Trends

8. Anti-infective Drugs Market Analysis, by Distribution Channel
8.1. Key Findings
8.2. Introduction
8.3. Anti-infective Drugs Market Value Share Analysis, by Distribution Channel
8.4. Anti-infective Drugs Market Forecast, by Distribution Channel
8.4.1. Hospital Pharmacy
8.4.2. Retail Pharmacy
8.4.3. Online Sales
8.5. Anti-infective Drugs Market Analysis, by Distribution Channel
8.6. Anti-infective Drugs Market Attractiveness Analysis, by Distribution Channel
8.7. Market Trends

9. Anti-infective Drugs Market Analysis, by Region
9.1. Global Market Scenario
9.2. Anti-infective Drugs Market Value Share Analysis, by Region
9.3. Anti-infective Drugs Market Forecast, by Region
9.3.1. North America
9.3.2. Europe
9.3.3. Asia Pacific
9.3.4. Latin America
9.3.5. Middle East & Africa
9.4. Anti-infective Drugs Market Attractiveness Analysis, by Region

10. North America Anti-infective Drugs Market Analysis
10.1. Key Findings
10.2. North America Anti-infective Drugs Market Overview
10.3. North America Anti-infective Drugs Market Value Share Analysis, by Country
10.4. North America Anti-infective Drugs Market Forecast, by Country
10.4.1. U.S.
10.4.2. Canada
10.5. North America Anti-infective Drugs Market Value Share Analysis, by Type
10.6. North America Anti-infective Drugs Market Forecast, by Type
10.6.1. North America Anti-infective Drugs Market Value Share Analysis, by Type - Anti-bacterial Drugs
10.6.2. North America Anti-infective Drugs Market Forecast, by Type - Anti-bacterial Drugs
10.6.2.1. B - Lactams
10.6.2.2. Quinolones
10.6.2.3. Macrolides
10.6.2.4. Tetracycline
10.6.2.5. Aminoglycoside
10.6.2.6. Others (Sulfonamide, Phenicols)
10.6.3. North America Anti-infective Drugs Market Value Share Analysis, by Type - Anti-fungal Drugs
10.6.4. North America Anti-infective Drugs Market Forecast, by Type - Anti-fungal Drugs
10.6.4.1. Azoles
10.6.4.2. Echinocandins
10.6.4.3. Polyenes
10.6.4.4. Others
10.6.5. North America Anti-infective Drugs Market Forecast, by Type - Anti-viral Drugs
10.7. North America Anti-infective Drugs Market Value Share Analysis, by Indication
10.8. North America Anti-infective Drugs Market Forecast, by Indication
10.8.1. Pneumonia
10.8.2. Methicillin-resistant Staphylococcus Aureus (MRSA)
10.8.3. Sepsis
10.8.4. Tuberculosis
10.8.5. Dermatophytosis
10.8.6. Aspergillosis
10.8.7. Candidiasis
10.8.8. Hepatitis Virus Infection
10.8.9. HIV Infection
10.8.10. Respiratory Virus Infection
10.8.11. Others
10.9. North America Anti-infective Drugs Market Value Share Analysis, by Distribution Channel
10.10. North America Anti-infective Drugs Market Forecast, by Distribution Channel
10.10.1. Hospital Pharmacy
10.10.2. Retail Pharmacy
10.10.3. Online Sales
10.11. North America Anti-infective Drugs Market Attractiveness Analysis

11. Europe Anti-infective Drugs Market Analysis
11.1. Key Findings
11.2. Europe Anti-infective Drugs Market Overview
11.3. Europe Anti-infective Drugs Market Value Share Analysis, by Country
11.4. Europe Anti-infective Drugs Market Forecast, by Country
11.4.1. U.K.
11.4.2. Germany
11.4.3. France
11.4.4. Italy
11.4.5. Spain
11.4.6. Rest of Europe
11.5. Europe Anti-infective Drugs Market Value Share Analysis, by Type
11.6. Europe Anti-infective Drugs Market Forecast, by Type
11.6.1. Europe Anti-infective Drugs Market Value Share Analysis, by Type - Anti-bacterial Drugs
11.6.2. Europe Anti-infective Drugs Market Forecast, by Type - Anti-bacterial Drugs
11.6.2.1. B - Lactams
11.6.2.2. Quinolones
11.6.2.3. Macrolides
11.6.2.4. Tetracycline
11.6.2.5. Aminoglycoside
11.6.2.6. Others (Sulfonamide, Phenicols)
11.6.3. Europe Anti-infective Drugs Market Value Share Analysis, by Type - Anti-fungal Drugs
11.6.4. Europe Anti-infective Drugs Market Forecast, by Type - Anti-fungal Drugs
11.6.4.1. Azoles
11.6.4.2. Echinocandins
11.6.4.3. Polyenes
11.6.4.4. Others
11.6.5. Europe Anti-infective Drugs Market Forecast, by Type - Anti-viral Drugs
11.7. Europe Anti-infective Drugs Market Value Share Analysis, by Indication
11.8. Europe Anti-infective Drugs Market Forecast, by Indication
11.8.1. Pneumonia
11.8.2. Methicillin-resistant Staphylococcus Aureus (MRSA)
11.8.3. Sepsis
11.8.4. Tuberculosis
11.8.5. Dermatophytosis
11.8.6. Aspergillosis
11.8.7. Candidiasis
11.8.8. Hepatitis Virus Infection
11.8.9. HIV Infection
11.8.10. Respiratory Virus Infection
11.8.11. Others
11.9. Europe Anti-infective Drugs Market Value Share Analysis, by Distribution Channel
11.10. Europe Anti-infective Drugs Market Forecast, by Distribution Channel
11.10.1. Hospital Pharmacy
11.10.2. Retail Pharmacy
11.10.3. Online Sales
11.11. Europe Anti-infective Drugs Market Attractiveness Analysis

12. Asia Pacific Anti-infective Drugs Market Analysis
12.1. Key Findings
12.2. Asia Pacific Anti-infective Drugs Market Overview
12.3. Asia Pacific Anti-infective Drugs Market Value Share Analysis, by Country
12.4. Asia Pacific rope Anti-infective Drugs Market Forecast, by Country
12.4.1. China
12.4.2. Japan
12.4.3. India
12.4.4. Australia & New Zealand
12.4.5. Rest of APAC
12.5. Asia Pacific Anti-infective Drugs Market Value Share Analysis, by Type
12.6. Asia Pacific Anti-infective Drugs Market Forecast, by Type
12.6.1. Asia Pacific Anti-infective Drugs Market Value Share Analysis, by Type - Anti-bacterial Drugs
12.6.2. Asia Pacific Anti-infective Drugs Market Forecast, by Type - Anti-bacterial Drugs
12.6.2.1. B - Lactams
12.6.2.2. Quinolones
12.6.2.3. Macrolides
12.6.2.4. Tetracycline
12.6.2.5. Aminoglycoside
12.6.2.6. Others (Sulfonamide, Phenicols)
12.6.3. Asia Pacific Anti-infective Drugs Market Value Share Analysis, by Type - Anti-fungal Drugs
12.6.4. Asia Pacific Anti-infective Drugs Market Forecast, by Type - Anti-fungal Drugs
12.6.4.1. Azoles
12.6.4.2. Echinocandins
12.6.4.3. Polyenes
12.6.4.4. Others
12.6.5. Asia Pacific Anti-infective Drugs Market Forecast, by Type - Anti-viral Drugs
12.7. Asia Pacific Anti-infective Drugs Market Value Share Analysis, by Indication
12.8. Asia Pacific Anti-infective Drugs Market Forecast, by Indication
12.8.1. Pneumonia
12.8.2. Methicillin-resistant Staphylococcus Aureus (MRSA)
12.8.3. Sepsis
12.8.4. Tuberculosis
12.8.5. Dermatophytosis
12.8.6. Aspergillosis
12.8.7. Candidiasis
12.8.8. Hepatitis Virus Infection
12.8.9. HIV Infection
12.8.10. Respiratory Virus Infection
12.8.11. Others
12.9. Asia Pacific Anti-infective Drugs Market Value Share Analysis, by Distribution Channel
12.10. Asia Pacific Anti-infective Drugs Market Forecast, by Distribution Channel
12.10.1. Hospital Pharmacy
12.10.2. Retail Pharmacy
12.10.3. Online Sales
12.11. Asia Pacific Anti-infective Drugs Market Attractiveness Analysis

13. Latin America Anti-infective Drugs Market Analysis
13.1. Key Findings
13.2. Latin America Anti-infective Drugs Market Overview
13.3. Latin America Anti-infective Drugs Market Value Share Analysis, by Country
13.4. Latin America Anti-infective Drugs Market Forecast, by Country
13.4.1. Brazil
13.4.2. Mexico
13.4.3. Rest of LATAM
13.5. Latin America Anti-infective Drugs Market Value Share Analysis, by Type
13.6. Latin America Anti-infective Drugs Market Forecast, by Type
13.6.1. Latin America Anti-infective Drugs Market Value Share Analysis, by Type - Anti-bacterial Drugs
13.6.2. Latin America Anti-infective Drugs Market Forecast, by Type - Anti-bacterial Drugs
13.6.2.1. B - Lactams
13.6.2.2. Quinolones
13.6.2.3. Macrolides
13.6.2.4. Tetracycline
13.6.2.5. Aminoglycoside
13.6.2.6. Others (Sulfonamide, Phenicols)
13.6.3. Latin America Anti-infective Drugs Market Value Share Analysis, by Type - Anti-fungal Drugs
13.6.4. Latin America Anti-infective Drugs Market Forecast, by Type - Anti-fungal Drugs
13.6.4.1. Azoles
13.6.4.2. Echinocandins
13.6.4.3. Polyenes
13.6.4.4. Others
13.6.5. Latin America Anti-infective Drugs Market Forecast, by Type - Anti-viral Drugs
13.7. Latin America Anti-infective Drugs Market Value Share Analysis, by Indication
13.8. Latin America Anti-infective Drugs Market Forecast, by Indication
13.8.1. Pneumonia
13.8.2. Methicillin-resistant Staphylococcus Aureus (MRSA)
13.8.3. Sepsis
13.8.4. Tuberculosis
13.8.5. Dermatophytosis
13.8.6. Aspergillosis
13.8.7. Candidiasis
13.8.8. Hepatitis Virus Infection
13.8.9. HIV Infection
13.8.10. Respiratory Virus Infection
13.8.11. Others
13.9. Latin America Anti-infective Drugs Market Value Share Analysis, by Distribution Channel
13.10. Latin America Anti-infective Drugs Market Forecast, by Distribution Channel
13.10.1. Hospital Pharmacy
13.10.2. Retail Pharmacy
13.10.3. Online Sales
13.11. Latin America Anti-infective Drugs Market Attractiveness Analysis

14. Middle East & Africa Anti-infective Drugs Market Analysis
14.1. Key Findings
14.2. Middle East & Africa Anti-infective Drugs Market Overview
14.3. Middle East & Africa Anti-infective Drugs Market Value Share Analysis, by Country
14.4. Middle East & Africa Anti-infective Drugs Market Forecast, by Country
14.4.1. GCC Countries
14.4.2. South Africa
14.4.3. Rest of MEA
14.5. Middle East & Africa Anti-infective Drugs Market Value Share Analysis, by Type
14.6. Middle East & Africa Anti-infective Drugs Market Forecast, by Type
14.6.1. Middle East & Africa Anti-infective Drugs Market Value Share Analysis, by Type - Anti-bacterial Drugs
14.6.2. Middle East & Africa Anti-infective Drugs Market Forecast, by Type - Anti-bacterial Drugs
14.6.2.1. B - Lactams
14.6.2.2. Quinolones
14.6.2.3. Macrolides
14.6.2.4. Tetracycline
14.6.2.5. Aminoglycoside
14.6.2.6. Others (Sulfonamide, Phenicols)
14.6.3. Middle East & Africa Anti-infective Drugs Market Value Share Analysis, by Type - Anti-fungal Drugs
14.6.4. Middle East & Africa Anti-infective Drugs Market Forecast, by Type - Anti-fungal Drugs
14.6.4.1. Azoles
14.6.4.2. Echinocandins
14.6.4.3. Polyenes
14.6.4.4. Others
14.6.5. Middle East & Africa Anti-infective Drugs Market Forecast, by Type - Anti-viral Drugs
14.7. Middle East & Africa Anti-infective Drugs Market Value Share Analysis, by Indication
14.8. Middle East & Africa Anti-infective Drugs Market Forecast, by Indication
14.8.1. Pneumonia
14.8.2. Methicillin-resistant Staphylococcus Aureus (MRSA)
14.8.3. Sepsis
14.8.4. Tuberculosis
14.8.5. Dermatophytosis
14.8.6. Aspergillosis
14.8.7. Candidiasis
14.8.8. Hepatitis Virus Infection
14.8.9. HIV Infection
14.8.10. Respiratory Virus Infection
14.8.11. Others
14.9. Middle East & Africa Anti-infective Drugs Market Value Share Analysis, by Distribution Channel
14.9.1. Hospital Pharmacy
14.9.2. Retail Pharmacy
14.9.3. Online Sales
14.10. Middle East & Africa Anti-infective Drugs Market Forecast, by Distribution Channel
14.11. Middle East & Africa Anti-infective Drugs Market Attractiveness Analysis

15. Competition Matrix
15.1. Anti-infective Drugs Market Share Analysis, by Company, 2016
15.2. Company Profiles
15.2.1. Merck & Co., Inc.
15.2.1.1. Company Profiles
15.2.1.2. Business Overview
15.2.1.3. Strategic Overview
15.2.1.4. SWOT Analysis
15.3. Bayer AG
15.3.1.1. Company Profiles
15.3.1.2. Business Overview
15.3.1.3. Strategic Overview
15.3.1.4. SWOT Analysis
15.4. Pfizer, Inc.
15.4.1.1. Company Profiles
15.4.1.2. Business Overview
15.4.1.3. Strategic Overview
15.4.1.4. SWOT Analysis
15.5. Gilead Sciences
15.5.1.1. Company Profiles
15.5.1.2. Business Overview
15.5.1.3. Strategic Overview
15.5.1.4. SWOT Analysis
15.6. GlaxoSmithKline plc
15.6.1.1. Company Profiles
15.6.1.2. Business Overview
15.6.1.3. Strategic Overview
15.6.1.4. SWOT Analysis
15.7. Novartis AG
15.7.1.1. Company Profiles
15.7.1.2. Business Overview
15.7.1.3. Strategic Overview
15.7.1.4. SWOT Analysis
15.8. Bristol-Myers Squibb Co
15.8.1.1. Company Profiles
15.8.1.2. Business Overview
15.8.1.3. Strategic Overview
15.8.1.4. SWOT Analysis
15.9. Sanofi
15.9.1.1. Company Profiles
15.9.1.2. Business Overview
15.9.1.3. Strategic Overview
15.9.1.4. SWOT Analysis
15.10. Allergen plc
15.10.1.1. Company Profiles
15.10.1.2. Business Overview
15.10.1.3. Strategic Overview
15.10.1.4. SWOT Analysis
15.11. F. Hoffman-La Roche Ltd.
15.11.1.1. Company Profiles
15.11.1.2. Business Overview
15.11.1.3. Strategic Overview
15.11.1.4. SWOT Analysis
15.12. Johnson and Johnson
15.12.1.1. Company Profiles
15.12.1.2. Business Overview
15.12.1.3. Strategic Overview
15.12.1.4. SWOT Analysis
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll